<DOC>
	<DOCNO>NCT01412294</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety Capecitabine/Cisplatin gastric cancer patient relapse adjuvant chemotherapy S-1 .</brief_summary>
	<brief_title>XParTS : Capecitabine/Cisplatin ( XP ) Recurrent Gastric Cancer</brief_title>
	<detailed_description>S-1/Cisplatin ( SP ) one standard treatment advance gastric cancer . However , evidence SP gastric cancer recurrence adjuvant therapy drug ( S-1 ) establish . The aim study evaluate efficacy safety Capecitabine/Cisplatin ( XP ) gastric cancer patient relapse adjuvant chemotherapy S-1 .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Recurrent gastric cancer histologically confirm adenocarcinoma 2 . Age 20 74 year either gender 3 . ECOG Performance Status 0 2 4 . Lesions confirm image within 28 day registration ( require measurable lesion define RECIST version 1.1 ) 5 . Postgastrectomy adjuvant chemotherapy include S1 least 12 week include interruption period 6 . Less 6 month treatmentfree interval completion adjuvant therapy 7 . In case receive neoadjuvant chemotherapy , total dose CDDP exceed 120mg/m2 8 . Treatmentnaïve recurrent gastric cancer 9 . Life expectancy least 3 month registration 10 . Written inform consent 11 . Adequate major organ function within 14 day registration 12 . Positive HER2 status 13 . Previous treatment platinum agent curative surgery 14 . Previous history serious hypersensitivity fluoropyrimidines platinum agent 15 . Previous history adverse reaction suggestive dihydropyrimidine dehydrogenase ( DPD ) deficiency 16 . More one cancer time one cancer different time separate 5year diseasefree interval . However , multiple active cancer include carcinoma situ skin cancer determine cured result treatment . 17 . Obvious infection inflammation ( pyrexia ≥ 38.0˚C ) 18 . Active hepatitis 19 . Heart disease serious require hospitalization , history disease within past year 9 ) Concurrent illness serious require hospitalization ( intestinal paralysis , intestinal obstruction , interstitial pneumonia pulmonary fibrosis , poorly control diabetes mellitus , renal failure , liver disorder , hepatic cirrhosis ) 10 ) Being treat need treatment phenytoin warfarin potassium 11 ) Chronic diarrhea ( watery stool ≥ 4 times/day ) 12 ) Active gastrointestinal hemorrhage 13 ) Body cavity fluid require drainage treatment 14 ) Clinical suspicion previous history metastasis brain meninges 15 ) Women pregnant , breastfeeding , potentially ( hop become ) pregnant 16 ) Unwillingness practice contraception 17 ) Poor oral intake 18 ) Psychiatric disorder may need treated psychotropics 19 ) Otherwise determine investigator site principal investigator unsuitable participation study</criteria>
	<gender>All</gender>
	<minimum_age>20 Weeks</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>capecitabine</keyword>
	<keyword>xp</keyword>
</DOC>